BDTX stock icon

Black Diamond Therapeutics
BDTX

$5.39
7.13%
 

About: Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

Employees: 54

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 6 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

376% more call options, than puts

Call options by funds: $243K | Put options by funds: $51K

85% more capital invested

Capital invested by funds: $107M [Q4 2023] → $198M (+$91.3M) [Q1 2024]

79% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 14

15% more funds holding

Funds holding: 75 [Q4 2023] → 86 (+11) [Q1 2024]

1.84% more ownership

Funds ownership: 73.82% [Q4 2023] → 75.66% (+1.84%) [Q1 2024]

9% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 22

Research analyst outlook

6 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$10
86%
upside
Avg. target
$12
123%
upside
High target
$16
197%
upside

6 analyst ratings

positive
100%
neutral
0%
negative
0%
Piper Sandler
Joseph Catanzaro
123%upside
$12
Overweight
Maintained
3 Jul 2024
HC Wainwright & Co.
Robert Burns
104%upside
$11
Buy
Reiterated
7 Jun 2024
HC Wainwright & Co.
Robert Burns
104%upside
$11
Buy
Maintained
16 May 2024
Wedbush
Robert Driscoll
197%upside
$16
Outperform
Maintained
8 Apr 2024
HC Wainwright & Co.
Robert Burns
123%upside
$12
Buy
Reiterated
18 Mar 2024

Financial journalist opinion